What's New in PAH?

Introduction Recent Events and Publications in PAH

Updates to Hemodynamic Definitions: PH

Updated Clinical Classification of Group 1:PAH

Group 1.3: Drug-and Toxin-Induced PAH

Group 1.5: PAH Long-Term Responders to Calcium Channel Blockers

Group 1.6: PAH With Overt Features of Venous/Capillaries (PVOD/PCH) Involvement

REVEAL Risk Score 2.0

REVEAL Risk Score 2.0 What Has Changed?

ESC/ERS Risk Assessment Categories for PAH

Risk Scores and Survival Analyses Based on REVEAL 2.0

Risk Scores Across Registries Based on REVEAL Update to 2.0

Registration Studies for Current PAH Therapies Study Duration and Primary Outcome Measure

Treatment Strategy and Evolution of Combination Therapy

Pharmacologic Agents for PAH Multiple Pathways

Treatment Algorithm for PAH Treatment-Naive

Treatment Algorithm for PAH Patient Already on Treatment

Reassessing and Modifying Treatment

Clinical Considerations: Does PAH Therapy Need Modification or Escalation?

Continual Re-Assessment of Risk Status

Implementation Strategies

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)